Endo S2 (Endoglycosidase S2): The "Molecular Scissors" for Antibody Glycosylation Modification
Endo S2 (Endo-β-N-acetylglucosaminidase S2) is a β-N-acetylglucosaminidase endoglycosidase derived from Streptococcus pyogenes serotype M49, demonstrating significant application value in the fields of glycobiology and antibody engineering.
- Recent Advances
- Product Information
Endo S2 is a β-N-acetylglucosaminidase endoglycosidase derived from Streptococcus pyogenes serotype M49, demonstrating significant application value in the fields of glycobiology and antibody engineering. As an IgG-specific glycosidase, Endo S2 can precisely cleave the glycosidic bond between the two innermost N-acetylglucosamine (GlcNAc) residues of the antibody Fc N-glycan, offering revolutionary implications for antibody drug development and quality control.
Endo S2 shares only 37% sequence homology with its counterpart Endo S but exhibits broader glycan substrate specificity. Recombinantly expressed Endo S2 has a molecular weight of approximately 92-110 kDa and features a C-terminal histidine tag for purification convenience.
Endo S2 possesses both hydrolytic and transglycosylation activities. The wild-type enzyme primarily exhibits robust hydrolytic activity, capable of deglycosylating ≥95% of IgG substrates within 30 minutes while retaining the core fucosylated GlcNAc structure. Studies show that Endo S2 is effective against all three major N-glycan types—complex, high-mannose, and hybrid—making it significantly superior to Endo S in terms of substrate breadth.
The optimal pH for enzymatic cleavage is 6.0-7.5, with commonly used buffer systems including PBS or Tris-HCl. Standard reaction conditions involve incubation at 37°C for 30-120 minutes, demonstrating good compatibility with common biological buffers.
| Feature Dimension | Endo S | Endo S2 | Comparative Interpretation and Significance |
|---|---|---|---|
| Substrate Specificity (Core Difference) | Narrower. Primarily cleaves core-fucosylated complex biantennary N-glycans (especially terminally galactosylated forms) with high efficiency. | Broader spectrum. In addition to core-fucosylated complex glycans, it efficiently cleaves: • High-mannose type • Hybrid type • Sialylated complex type |
Endo S2 is a "versatile player," capable of handling more antibody glycoforms, with wider applications—particularly suitable for analyzing recombinant antibodies with atypical glycan structures. |
| Catalytic Efficiency | Highly efficient for specific substrates (e.g., fucosylated biantennary glycans of human IgG1). | Generally higher or comparable, and due to its broader substrate range, it delivers more stable and efficient overall performance across diverse glycoforms. | For complex samples or scenarios requiring uniform processing, Endo S2 provides more reliable and thorough deglycosylation results. |
| Cleavage Site | Identical for both: Hydrolysis occurs between the two N-acetylglucosamine (GlcNAc) residues of the chitobiose core, releasing the intact glycan chain while leaving one core GlcNAc on the protein. | Identical mechanism of action, ensuring product consistency as highly specific endoglycosidases. | |
| Primary Application Advantages | • Ideal tool for specific fucose removal, used in ADCC enhancement studies. • Early-stage glycan profiling. |
• Comprehensive antibody deglycosylation tool, suitable for removal and preparation of various glycoforms. • Ideal choice for glycomics analysis, releasing a wider variety of glycans from complex samples. • Greater versatility in producing homogeneous antibodies. |
Endo S is a "special forces unit," specialized in ADCC-enhancing pathways; Endo S2 is a "universal soldier," offering broader utility in basic research, drug development, and quality control. |
| Limitations | Low or no activity against non-fucosylated, high-mannose, or hybrid glycans. | Due to its broad spectrum, it may be less precise than Endo S in scenarios requiring selective removal of only fucosylated glycans. | Selection depends on the goal: If targeting fucose removal for ADCC enhancement, Endo S may be more direct; for comprehensive analysis or removal of all glycoforms, Endo S2 is the superior choice. |
Simply put, Endo S2 is a "functionally enhanced version" of Endo S. While retaining Endo S's high specificity (exclusive IgG Fc cleavage) and efficiency, engineered modifications significantly expand its "target range", enabling it to process nearly all common IgG N-glycan types. This makes Endo S2 a more powerful and versatile standard tool in modern antibody engineering, glycomics analysis, and biopharmaceutical process development. The original Endo S retains value in studies requiring highly specific focus on core fucose removal.
1. Antibody Drug Development and Engineering
ADCC enhancer: By removing core fucose from therapeutic antibodies (e.g., rituximab, trastuzumab), it directly and efficiently enhances their cancer cell-killing effects.
Homogeneous antibody production: Enzymatic deglycosylation of antibodies in vitro yields glycoform-uniform products for studying the impact of specific glycoforms on pharmacokinetics, immunogenicity, and efficacy.
Site-specific conjugation: The exposed core GlcNAc serves as a specific site for chemical or enzymatic introduction of new functional groups (e.g., toxins, fluorescent labels, PEG), enabling precise antibody conjugation.
2. Glycomics and Structural Biology
Glycan profiling: As a critical sample preparation tool, it specifically releases IgG N-glycans from complex samples for high-throughput glycan sequencing and quantitative analysis.
Structure determination: Prepares glycan-free antibody samples for X-ray crystallography or cryo-EM studies, revealing clearer molecular details of antibody-antigen or antibody-receptor interactions.
3. Novel Therapeutic Strategies
Enzymatic immunomodulation: Explores direct in vivo use of Endo S2 to selectively remove glycans from pathological autoantibodies or inflammatory antibodies, modulating their effector functions and offering new approaches for treating autoimmune diseases (e.g., rheumatoid arthritis, lupus).
Antibody recycling and reuse: In extracorporeal blood perfusion devices, Endo S2-modified antibodies may alter their biological fate.
The discovery of Endo S2 and its glycosynthase mutants provides an efficient and flexible technological platform for antibody glycoengineering. From basic research to biopharmaceuticals, this molecular tool is driving therapeutic antibodies toward greater precision and efficacy, with broad application prospects.
| Catalog No. | Product Name |
|---|---|
| UA070055 | Endo S2 |
| UA070039 | Endo S |
| UA070081 | M-bovin-GalT1(Y289L) |
Recommended article: https://mp.weixin.qq.com/s/-zsBA_uFu3q6nbg_i-VWKw
Tiezheng Li; Xin Tong; Qiang Yang; John P. Giddens; Lai‐Xi Wang. Glycosynthase Mutants of Endoglycosidase S2 Show Potent Transglycosylation Activity and Remarkably Relaxed Substrate Specificity for Antibody Glycosylation Remodeling. Journal of Biological Chemistry,2016.
This article is reviewed and published by the technical expert team of UA
Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.
Purchase recombinant protein, choose Nanjing UA-Bio
UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.
Business license (three certificates in one) 